Biogen Inc BIIB Q1 2026 Earnings Preview New Launch Momentum and MA Outlook Amid Legacy MS Franchise Headwinds How INVESCO IVR stacks up against analyst expectations Risk Aversion 20260511 First FMY Stock Buyback Program 021 20260420 Is Kura Oncology KURA stock attractive for portfolio addition Q4 2025 Below Expectations AKTS Aktis reports quarterly results amid clinical pipeline progress investors await strategic update on oncology trials